<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827671</url>
  </required_header>
  <id_info>
    <org_study_id>NL23124.041.08</org_study_id>
    <secondary_id>2008-002203-13</secondary_id>
    <nct_id>NCT00827671</nct_id>
  </id_info>
  <brief_title>Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma</brief_title>
  <acronym>TRACC</acronym>
  <official_title>Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>P.O. Witteveen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of the combination between&#xD;
      cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is&#xD;
      safe and adds efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims at developing a novel strategy to optimize the treatment of oesophageal&#xD;
      adenocarcinoma and gastro-oesophageal junctional tumors with curative intent. Surgery in&#xD;
      combination with peri-operative chemotherapy, using the combination epirubicin, cisplatin and&#xD;
      5-FU, as defined by the recent MAGIC trial, results in 13% increase in 5-yr survival. To&#xD;
      improve the outcome of patients with this disease we hypothesize that the addition of&#xD;
      pre-operative combined cetuximab-radiotherapy (cetux-RT) treatment could improve the outcome&#xD;
      of this patient category through better local control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Experimental treatment not feasible due to high rate of drop out&#xD;
  </why_stopped>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete remission</measure>
    <time_frame>1 month</time_frame>
    <description>determination of tumor residual cell content in surgical specimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resectability rate defined as the number of patients abke to undergo resection after neo-adjuvant treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events during neo-adjuvant treatment as defined by NIH CTCAE v3.0</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications in the post-operative period (defined as 4 weeks after surgery) that can be attributed to surgical procedures</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define local (locoregional lymphnode metastasis as defined by TNM classification/ malignant peritonitis/ solid masses within the anatomic region of the esophagus) vs distant metastases as first manifestation of recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of R0 resection determined by the pathologist</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Resectable Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Pre-operative chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment</description>
    <arm_group_label>Pre-operative chemotherapy</arm_group_label>
    <other_name>erbitux</other_name>
    <other_name>c225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy to oesophageal tumour</intervention_name>
    <description>45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk</description>
    <arm_group_label>Pre-operative chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven resectable adenocarcinoma of the lower oesophagus and&#xD;
             gastric-oesophageal junction&#xD;
&#xD;
          -  Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax&#xD;
             and abdomen and ultrasound neck region. For the patients treated in this study the&#xD;
             gastro-oesophageal junctional tumors will be staged as oesophageal tumors with respect&#xD;
             to their lymphnode metastases.&#xD;
&#xD;
          -  Age &gt;18y and written informed consent after at least 4 days of deliberation time from&#xD;
             the moment the patient information has been given and has been explained.&#xD;
&#xD;
          -  Weight loss &lt; 10% in 0.5 yr&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous malignancy other than basal cell carcinoma of the skin or local resection for&#xD;
             cervical carcinoma in situ.&#xD;
&#xD;
          -  Inadequate organ function as defined by:&#xD;
&#xD;
          -  Inadequate haematology (Hb &lt; 5,5 mmol/L (red blood cell transfusions are allowed to&#xD;
             increase the Hb at the discretion of the investigator) - neutrophils &lt; 1,5 109/L&#xD;
             -platelets &lt;100*109/L),&#xD;
&#xD;
          -  Liver enzyme elevation (bili &gt; 1,5*ULN - ASAT &gt; 2,5*ULN - ALAT &gt; 2,5*ULN) or&#xD;
&#xD;
          -  Impaired renal function (creatinine clearance by cockcroft &lt; 60 cc/min)&#xD;
&#xD;
          -  Proteinuria &gt;1,0gr/24hr&#xD;
&#xD;
          -  Tumour stage: M1a and/or tumour length &gt; 8 cm and/or &gt; 5 cm radially&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to the start of study treatment&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Known allergy to one of the study drugs used&#xD;
&#xD;
          -  Use of any substance known to interfere with the chemotherapy clearance&#xD;
&#xD;
          -  Previous radiotherapy to the chest&#xD;
&#xD;
          -  Significant concomitant diseases preventing the safe administration of study drugs or&#xD;
             likely to interfere with study assessments&#xD;
&#xD;
          -  Uncontrolled angina pectoris; cardiac failure or clinically significant arrhythmias&#xD;
&#xD;
          -  Continuous use of immunosuppressive agents&#xD;
&#xD;
          -  Concurrent use of the antiviral agent sorivudine or chemically related analogues, such&#xD;
             as brivudine&#xD;
&#xD;
          -  Prior exposure to anti-EGFR targeting agents.&#xD;
&#xD;
          -  Hearing loss &gt; 25 dB under normal&#xD;
&#xD;
          -  Neurotoxicity &gt; CTC grade 1&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Patients (M/F) with reproductive potential not implementing adequate contraceptive&#xD;
             measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. P. Lolkema, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>P.O. Witteveen</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

